Back to Archived News
Global Health Ventures Expands Patent Portfolio
Monday, October 18, 2010
Vancouver, British Columbia -- Global Health Ventures Inc. (OTCBB:GHLV) (the "Company") is a specialty pharmaceutical company focused on sublingual (under the tongue) drug delivery. The Company's sublingual formulation is designed to enhance drugs to be delivered to the body without the need for injection. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly and efficiently. This technology works well for drugs that need faster results or have major side effects associated with gastrointestinal and/or liver break down.
The Company is pleased to announce that it has filed a new United States Provisional Patent on over 40 drugs for sublingual delivery. These include: Quinapril, Triprolidine, Tadalafil, Pioglitazone, Nifedipine, Epinephrine, Salbutamol, Alfentanil, Allopurinol, Glimepiride, Naratriptan, Aminophylline, Clomipramine, Latrodectus mactant, Alprazolam, Baclofen, Carvedilol, Divalproex, Famotidine, Propranolol, Salbutamol, Fentanyl, Almotriptan, Alendronate, Celebrex, Morphine, Codeine, Warfarin, Steroids, Metforming, Adrenalin, Lidocaine, Vallium, Diltiazem, Claritin, Dantrolene, Zopiclone, Leuprolide, Oxycodone, Fosamax, and Dalteparin.
Some of the drugs chosen here are for developing new therapeutic indication by using a rapid low dose delivery system. Some other drugs are selected because they have a very low bioavailability for oral administration. The sublingual delivery system can increase their bioavailability. Finally, some other drugs are chosen because of the gastrointestinal and liver side effects associated with the oral route. The sublingual route shall bypass those side effects. The Company strongly believes that its formulation shall apply to all the above drugs and perhaps many more.
"We realize that the development of such a vast portfolio of drugs requires substantial financial resources. However, we do not plan to develop all the products with our own resources. Our plan would be to enter into partnership with major pharmaceutical companies for each product. A partnership with well established companies should provide sufficient funding to develop and commercialize the products and share profits. The Company is already in discussion with few large pharmaceutical companies that are very interested in working with us on developing and commercializing some of these drugs," said Dr. Hassan Salari, Global Health President & CEO.
About Global Health Ventures
Global Health Ventures is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite is presently in clinical development in Europe. The Company's second drug "Relax-B" is also under development in Canada for anxiety. And, the third drug will be an anti-migraine drug. The Company plans to use the same technology to deliver a vast number of other FDA approved and non-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include stress relief, sleeping disorders, pain killers, anti-allergy medications, energy boosters and addiction replacement therapies.
Notice Regarding Forward Looking Statements
This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.
Back to Archived News
